Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

The MHRA has accepted the marketing authorization application for Anktiva combined with BCG for BCG-unresponsive NMIBC with CIS in the UK. Anktiva received FDA approval in the US in April 2024, and ...

“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD. In this video, Laurence Albiges, MD, PhD, shares final results from the phase 3 ...

"What we're really trying to see now is this integration of imaging and using it with respect to AI and planning," says Dean S. Elterman, MD, MSc, FRCSC. In this video, Dean S. Elterman, MD, MSc, ...

Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...

“While there are other treatment options available for treating BPH, there remains a significant need for much less invasive treatment approaches that can preserve and protect the integrity of the ...

Real-world outcomes with nadofaragene point to safety, efficacy of NMIBC treatment ...